Skip to main content
. 2021 Jun 14;21:567. doi: 10.1186/s12879-021-06237-x

Fig. 2.

Fig. 2

Cumulative incidences of mortality during treatment with tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir in patients with HBV-related ACLF. ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate